INS and Stroke: A decrease in body weight, blood pressure, HbA1c, fasting insulin, insulin resistance, plasma glucagon, total cholesterol, lipids, FPG, SMBG, cardiovascular death, nonfatal stroke, and myocardial infarction are observed with the use of semaglutide in monotherapy or in combination with other antidiabetic drugs.